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SnoN (Ski-novel protein) plays an important role in embryonic development, tumorigenesis and
aging. Past studies largely focused on its roles in tumorigenesis. Recent studies of its expression pat-
terns and functions in mouse models and mammalian cells have revealed that SnoN interacts with
multiple signaling molecules at different cellular levels to modulate the activities of several signal-
ing pathways in a tissue context and developmental stage dependent manner. These studies suggest
that SnoN may have broad functions in the embryonic development and tissue morphogenesis.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
SnoN (Ski novel protein) is a member of the Ski family of pro-
teins and was initially identiﬁed as a nuclear proto-oncoprotein
based largely on its close homology to v-ski, the transforming
protein of the avian Sloan-Kettering retrovirus [1,2] and on its
ability to induce anchorage-independent growth of chicken and
quail embryo ﬁbroblasts when overexpressed [3]. In addition to
SnoN (684 amino acids), three alternatively spliced isoforms of
SnoN, SnoN2 (638 amino acids), SnoA (415 amino acids) and SnoI
(399 amino acids), all containing an identical N-terminal region of
366 amino acid residues, have been reported [4–6]. Apart from
SnoN2, which is an abundant isoform in normal mouse tissues,
the expression of SnoI and SnoA is limited to speciﬁc human cancer
cell lines, and their functions in these cells have not been deﬁned.
The N-terminal 366 amino acid-residue region common to all iso-
forms is encoded by exon 1 of the snoN gene and shows a high level
of sequence homology to Ski (Fig. 1). This ski homology region
appears to mediate most if not all the known biological functions
of Ski and SnoN. The carboxyl (C)-terminal halves of Ski and SnoN
show little sequence homology, but may mediate homo- or het-
ero-dimerization with each other [7,8]. Although SnoN displays a
certain degree of structural and functional redundancy with Ski,
more recent studies suggest that SnoN also differs signiﬁcantly
from Ski in its functions and regulatory mechanisms [9–11]. SnoNal Societies. Published by Elsevier
Molecular and Cell Biology,
eley, CA 94720, USA. Fax: +1is expressed ubiquitously throughout embryonic development
and in all adult tissues and cells, suggesting that it may play a role
in embryonic development and normal tissue morphogenesis and
homeostasis. Most past studies on SnoN have focused on its actions
in human cancers or cancer-derived cell lines as well as its regula-
tory and signaling mechanisms [9–11]. The physiological function
of SnoN during embryonic and postnatal development has not been
well characterized. In this review, we will focus on the recent pro-
gresses in understanding the functions of SnoN in embryogenesis
and tissuemorphogenesis with a brief summary of themechanisms
of SnoN signaling and expression. A more detailed summary of
these mechanistic studies and the role of SnoN in tumorigenesis
can be found in other reviews [10,11].
2. Regulation of SnoN expression
The expression of SnoN in mammalian cells is dynamically reg-
ulated and under a precise temporal and spatial control. Regulation
of SnoN expression occurs at multiple levels, including transcrip-
tional regulation, protein degradation and subcellular localization
[9–11]. SnoN expression can be induced during speciﬁc stages of
tissue morphogenesis, by growth factors such as TGF-b, upon tis-
sue injury, and in response to a variety of cellular stress signals
including oxidative stress and chronic DNA damage [10,11].
The best characterized regulator of SnoN expression is TGF-b.
TGF-b regulates SnoNexpressionat both the level of protein stability
and transcriptional activation [9–11]. UponTGF-b stimulation, SnoN
is rapidly degraded to allow the formation of a transcriptionally ac-
tive Smad complex to activate the expression of TGF-b target genes
[12]. This degradation of SnoN depends on ubiquitin-dependentB.V. Open access under CC BY-NC-ND license.
Fig. 1. Domain structure and signaling activities of SnoN. SnoN is a protein of 684 amino acids residues with a conserved ski-homology domain (green), that contains the
R-Smad-binding site (blue), a SAND (Sp100, AIRE1, NucP41/75, and DEAF1)-like domain (red) that mediates binding to Smad4. The p53 and PML binding regions are indicated
by the arrowheads. Upon induction, SnoN can bind to the Smad proteins to antagonize the cytostatic activity of TGF-b. Upon induction by cellular stress signals, high levels of
SnoN can be recruited to the PML nuclear bodies, where it interacts with p53, leading to its stabilization and activation. This ability to induce p53-dependent senescence and
apoptosis responses underlies its anti-tumorigenic activity and its ability to promote aging. In the mammary gland, SnoN is induced by TGF-b and prolactin in a synergistic
manner. The elevated SnoN enhances STAT5 stability, thereby sharply increasing the activity of prolactin signaling to trigger the onset of lactation.
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including Smad ubiquitin regulatory factor 2 (Smurf2) [13], the
Anaphase Promoting Complex (APC/C) [14,15] or Arkadia [16–18].
SnoN itself is also a transcription target of TGF-b. Transcription of
SnoN is induced after 2 hours of TGF-b treatment by a direct binding
of the Smad2/4 complex to the Smad-binding elements in the snoN
promoter [12,19]. This upregulation of SnoN expression may func-
tion as a negative feedbackmechanism to regulate the timing, dura-
tion and robustness of TGF-b signaling and may also participate in
other cellular events [19]. SnoN transcription can also be induced
by other growth factors, such as Hepatocyte growth factor (HGF)
[20,21] and prolactin [22], upon tissue injury [23,24], and in
response to oxidative stress, oncogene overexpression and chronic
DNA damage (unpublished observations). The pathways andmech-
anisms involved in these regulations have not been fully deﬁned.
SnoN was originally identiﬁed as a nuclear protein in estab-
lished cell lines. However, more recent work suggests that in nor-
mal tissues and non-tumorigenic or primary epithelial cells, SnoN
is predominantly expressed in the cytoplasm, while in cancer cell
lines and some malignant tissues, it is nuclear [25,26]. Recently,
we found that in mouse endothelial cells, a population of SnoN
co-localizes with ALK1 on the plasma membrane to facilitate
activation of Smad1/5/8 (unpublished data). Thus, SnoN localiza-
tion may be regulated in a cell type speciﬁc manner and also sub-
jected to regulation by the surrounding microenvironment and
cell–cell interaction.
3. Mechanism of SnoN functions
SnoN has been shown to activate a number of signaling path-
ways, in some cases in a cell type-speciﬁc manner to regulate cell
proliferation, apoptosis, senescence and differentiation (Fig. 1).3.1. SnoN as a modulator in TGF-b signaling
SnoN is an important regulator of the Smad proteins of the TGF-b
signaling pathways [9–11,27]. Members of TGF-b superfamily,
including TGF-bs, activin, Nodal and BMPs (GDFs), play essential
roles in embryonic development, organ formation, tissue homeo-
stasis and cell–microenvironment interaction [28–32]. In particu-
lar, Nodal, the ﬁrst TGF-b family member to be expressed in the
embryo, is a morphogen whose concentration gradient is essential
for gastrulation and establishment of anterior-posterior and left-
right axes [33]. TGF-b1 ligand and its downstream signaling compo-
nents are critical for yolk sac and embryonic angiogenesis and are
also important for the maturation and maintenance of vasculature
in adult animals [34]. These growth factors signal through the cell
surface type II and I receptor kinases and downstream Smad pro-
teins. Binding of ligands to their speciﬁc type II receptors results
in activation of the type I receptor kinases, which then phosphory-
late and activate Smad (R-Smad) proteins. Inmammals, seven type I
receptors, ALK1-7, and ﬁve type II receptors function in combina-
tion to activate two major branches of R-Smads, Smad2/Smad3
and Smad1/Smad5/Smad8. TGF-b/Activin/Nodal signals mainly
through Smad2/Smad3, while BMP/GDF predominantly activates
Smad1/Smad5/Smad8 [27,35–38]. The phosphorylated R-Smads
then form heteromeric complexeswith the common partner Smad4
and translocate into the nucleus where they bind DNA, interact
with various cellular co-factors and activate transcription of multi-
ple target genes, leading to different cellular responses.
SnoN interacts with Smad2, Smad3 and Smad4 in both the cyto-
plasm and nucleus and represses their ability to activate down-
stream target genes by preventing their nuclear translocation,
disrupting the functional heteromeric Smad complexes, recruiting
transcription co-repressor complexes and blocking the binding of
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ity of SnoN to antagonize Smad2, Smad3 and Smad4 implies that
SnoN may function as a regulator of TGF-b, activin and Nodal path-
ways. Indeed, in cultured human and murine cell lines, SnoN has
been shown to repress the expression of TGF-b target genes and
block the cytostatic responses to TGF-b [12,42], and this is sug-
gested to be responsible for the pro-oncogenic activity of SnoN in
lung and breast cancer cell lines [43]. During embryogenesis
in vivo, the ability of SnoN to regulate Smad2/Smad3 has been
shown to be necessary for the TGF-b and Nodal-dependent devel-
opmental events (see below).
The effect of SnoN on the Smad proteins is not always inhibi-
tory. In endothelial cells, SnoN also promotes activation of
Smad1/Smad5 (Fig. 2 and see below for more details). In mink lung
epithelial cells, reducing SnoN expression has been found to impair
TGF-b-dependent transcription and cell cycle arrest [44,45], sug-
gesting that at a lower expression level, SnoN may function to pro-
mote TGF-b signaling. Since this has only been observed in only
one cell line, it is unclear how common this effect is and what
the underlying mechanism is.
3.2. SnoN as an activator of p53
Independent of its ability to antagonize TGF-b-induced growth
inhibition, SnoN also functions to transduce signals in the cellular
stress pathways by activating p53. SnoN expression is upregulated
by a number of stress signals including chronic DNA damage, oxida-
tive stress and oncogene overexpression (unpublished observa-
tions), and the elevated SnoN is recruited to the PML nuclear
bodies through a direct physical interaction with the PML protein
[46]. In the PML nuclear bodies, SnoN can bind directly to p53
and compete with Mdm2 for binding to p53, preventing p53 ubiq-
uitination and degradation and facilitating p53 acetylation andFig. 2. SnoN signaling in endothelial cells. SnoN plays a key role in angiogenesis
through regulating the balance of two branches of TGF-b signaling in endothelial
cells. SnoN enhances activation of Smad1/5 by ALK1 while represses the activity of
the ALK5 branch, thus promoting endothelial cell proliferation and migration.phosphorylation, leading to p53 stabilization and activation [47].
Through this activity, overexpression of SnoN in both epithelial
and ﬁbroblast cells trigger senescence and increased apoptotic re-
sponses. This ability of SnoN to activate p53 to induce cell senes-
cence is not only responsible for its anti-tumorigenic activity, but
also results in accelerated aging [47]. Knockin mice expressing a
form of SnoN that is accumulated to a high level are resistant to
chemical carcinogen-induced tumorigenesis in a p53-dependent
manner, are more sensitive to environmental stress and display
premature aging in aspects that are known to be p53-dependent
[47]. Thus, in adult cells, SnoN is not just an important negative reg-
ulator of TGF-b signaling, but plays a much broader role in co-coor-
dinating the cellular stress responses by activating the p53 pathway
to regulate cell cycle arrest, senescence and apoptosis.
3.3. Other cell or tissue-speciﬁc pathways activated by SnoN
SnoN has been shown to regulate a number of signaling path-
ways in a tissue-speciﬁc manner. In the mammary gland, SnoN is
required for the onset of lactation by promoting prolactin signaling
through inducing stabilization of STAT5 proteins [22]. SnoN-null
mice show a dramatically reduced STAT5 expression and activa-
tion, leading to lactation failure [22]. In rat granule neurons, SnoN
may function as a transcriptional activator to regulate the expres-
sion of a number of genes required for axon development [48]. For
example, SnoN coordinates with p300 to activate the transcription
of the actin-binding protein Ccd1 to promote axon growth [48]. It
is likely that SnoN may be involved in crosstalk with more signal-
ing pathways in speciﬁc cell types to regulate cell differentiation
and tissue morphogenesis.
3.4. SnoN expression and functions in embryogenesis
SnoN is ubiquitously expressed in the mouse embryo, and its
expression is selectively upregulated during speciﬁc stages of
embryogenesis in tissues with a high degree of proliferative activ-
ity [5,26]. In mouse embryos, SnoN transcript is detected as early
as E6.5 post coitum (p.c.) in the epiblast and the extramembryonic
tissue [5]. Later it is highly expressed in the anterior endoderm,
neuroectoderm and neural headfolds (unpublished observations).
By E9.5 p.c., elevated SnoN mRNA is found in neural tissues and
neural crest cells in addition to the developing vasculature, limb
buds and mandibular arches. By E12.5, SnoN expression reaches
the highest level in the central nervous system and remains ele-
vated in the brain until birth. In addition, SnoN is induced from
E11.5–E15.5 in skeletal muscles. The expression pattern of SnoN
in the embryos suggests that it plays a role in the development
of multiple lineages including vasculature, neuronal structures
and skeletal muscles.
The functions of SnoN in embryonic development have not been
well deﬁned. Three snoN knockout mouse lines have been gener-
ated, all of which contain deletions of exon 1 and part of the snoN
promoter region. One SnoN-null line shows embryonic lethality
before E3.5 [49]. The other two SnoN/ lines are viable and only
show a moderate defect in T cell activation [50]. While the reason
underlying this discrepancy in phenotypes is not clear, these
knockout mice fail to be informative regarding the role of SnoN
in embryogenesis. Given the important and complex roles that
TGF-b family members play in embryogenesis, we reason that if
SnoN is a crucial regulator of the Smad proteins, disruption of
the SnoN–Smad interaction may lead to severe developmental out-
comes. We therefore generated a knockin mouse (SnoNm/m)
expressing a mutant SnoN defective in binding to the Smad pro-
teins in the original snoN locus [46]. Analysis of this knockin mouse
strain has revealed important functions of SnoN in mammalian
embryogenesis.
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The SnoNm/m mice show partial embryonic lethality where
approximately 33% of the embryos die before E12.5 [46], duemainly
to defects in angiogenesis in both the yolk sac and embryo body
(unpublished data). These SnoNm/m embryos display severe growth
retardation, and their yolk sacs are pale and wrinkled with aberrant
vasculature composed of dilated blood vessels surrounded by de-
creased numbers of vascular smooth muscle cells. The embryo
bodies exhibit defects in secondary and tertiary vessel branching.
They also exhibit dilated or collapsed dorsal aorta and pericardial
effusion due to defects in both endothelial cell function and in
recruitment and differentiation of vascular smooth muscle cells
[51]. These phenotypes are very similar to those shown inmice lack-
ing ALK1 or Smad5 [51–55], suggesting that SnoN regulates angio-
genesis through modulating TGF-b signaling in endothelial cells.
In endothelial cells, TGF-b signals through two branches: the
conventional ALK5-Smad2/3 branch and the endothelial speciﬁc
ALK1-Smad1/5 branch [51,56]. Both branches are activated upon
ligand binding but exert different effects on endothelial cell prolif-
eration and migration. The ALK1 branch promotes endothelial cell
proliferation and migration, while the ALK5 branch represses these
processes, leading to the maturation phase of angiogenesis. The
proper balance of the two signaling branches is necessary for
angiogenesis.
Using mouse embryo endothelial cells (MEECs) isolated from
the SnoNm/m embryos, we found that disruption of the SnoN–Smad
interaction leads to not only elevated activation of the ALK5
branch, but also decreased ALK1 signaling activity (unpublished
data). While WT SnoN can directly bind to ALK1 upon TGF-b treat-
ment to promote its phosphorylation and activation of Smad1/5,
mutant SnoN fails to bridge ALK1 with Smad1/5, resulting in
decreased Smad1/5 activation (unpublished data). Thus, in endo-
thelial cells, SnoN promotes Smad1/5 activation while repressing
Smad2/3 activity to regulate the proper balance of overall TGF-b
signaling (Fig. 2). This balance also controls the expression level
of TGF-b1 itself, which in turn modulates the strength of angio-
genic signals (unpublished data). Thus, SnoN is an integral part of
the TGF-b signaling network and can act as an activator of the
Smad proteins in addition to the reported negative regulatory role.
3.6. SnoN in regulation of forebrain development
Independent of the angiogenesis defects, approximately one
third of the homozygous embryos that died before E12.5 and a
fraction of the heterozygous embryos exhibit aberrant formation
or patterning of the anterior neural structures with varying degrees
of severity. These defects range from anterior truncations, absence
of eye development to failure in neural tube closure and holo-
prosencephly (unpublished observations). Since the development
of the midline structure and anterior patterning of the brain
depend on optimal Nodal signaling activity [57], the above pheno-
types suggest a role of SnoN in modulating Nodal-dependent
developmental events. Indeed, SnoN can repress Nodal-dependent
transcription in cells. Analysis of the expression of a number of
Nodal target genes in individual embryos at E6.5 and E7.5 revealed
that Nodal signaling in SnoNm/m embryos display a dramatic in-
creased oscillation in comparison to that in WT embryos (unpub-
lished observations), indicating that SnoN functions to limit the
extent of signaling ﬂuctuation and to maintain robustness of the
Nodal signaling circuit.
Apart from angiogenesis and anterior forebrain development, a
number of other phenotypes found in SnoNm/m embryos, such as
neural tube closure, may be related to defective BMP signaling
[58]. Although SnoN has not been found to directly antagonize
BMP signaling through Smad1/5/8 proteins, it may indirectly affectBMP target gene expression in vivo through yet-to-be-identiﬁed
mechanisms. Taken together, analysis of the SnoNm/m embryos
suggests that SnoN can function as both an activator and repressor
of Smad proteins dependent on tissue or cell types. Instead of
inhibiting TGF-b signaling, SnoN is an integral part of the TGF-b
superfamily signaling circuit and is necessary for maintaining the
robustness of this signaling network.4. SnoN expression and functions in adult tissue morphogenesis
SnoN is ubiquitously expressed in all adult cell types at a low
level [2,5,6]. Recent study in normal human esophageal, ovarian,
breast and pancreatic tissues indicate that it is found in both tissue
epithelia and stroma and is predominantly cytoplasmic [26,59,60].
Given its ubiquitous expression pattern, SnoN is expected to func-
tion in normal tissue physiology likely in a tissue speciﬁc manner.
However, very little is known about its function in these processes.
Here we summarize the recent works that provide insights on SnoN
function in mammary gland development and in axon growth.
4.1. SnoN in the mammary gland
The expression and functions of SnoN in mouse mammary
gland development have been well characterized in recent years.
SnoN is detected in the cytoplasm of luminal epithelial cells lining
the ducts and epithelial cells of lobuli and terminal ducts. Its
expression is low in the virgin gland, but sharply up regulated at
late pregnancy and at the beginning of lactation [26]. The peak per-
iod of SnoN expression correlates with the structural and func-
tional differentiation of the mammary alveoli, which polarize to
form the secretory alveolar epithelium capable of milk production
and secretion [61–64]. The high expression level of SnoN during
this window suggests that it may play an important role in the
structural and functional differentiation of the alveolar epithelial
cells and that the expression of SnoN might be regulated by the
pregnancy hormones.
Indeedwe found that this sharp upregulation of SnoN expression
at late pregnancy is induced by the synergistic actions of TGF-b and
prolactin [22]. The elevated SnoN subsequently promotes STAT5
expressionandactivationbyenhancing its stability, at the same time
relieving the repressive effects of TGF-b on prolactin signaling. This
allows a rapid increase in prolactin/STAT5 signaling to trigger the
onset of lactation. SnoN/mice display severe defects in lactogene-
sis, and mammary epithelial cells from these mice fail to proliferate
andundergo propermorphogenesis in a three-dimensionalmatrigel
model [22]. These defects can be rescued by an active STAT5. Thus,
SnoN is a critical player in the regulation of milk production and
mammary alveologenesis through promoting STAT5 signaling.
In addition to its role at the onset of lactation, SnoN also stimu-
lates mammary epithelial cell proliferation in the virgin gland.
Transgenic mice overexpressing a SnoN fragment under the control
of themousemammary tumor virus promoter show increased side-
branching and lobular-alveolar proliferation in the virgin glands
[26]. High levels of SnoN also accelerate post-lactational involution
by inducingan increase in apoptosis anda reduction in survival cues.
These activities of SnoN are likely dependent on its ability to repress
TGF-b signaling since TGF-b has been shown to inhibit lobular alve-
olar proliferation, ductal growth [65], and regulate involution [66].
In addition, although overexpression of SnoN is insufﬁcient to in-
duce mammary tumorigenesis, elevated levels of SnoN cooperate
withpolyomamiddle T antigen to acceleratebreast adenocarcinoma
development and pulmonarymetastases [26]. Taken together, SnoN
affects multiple stages of mammary gland development by regulat-
ing the proliferation, differentiation, polarity and apoptosis ofmam-
mary epithelial cells.
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In the adult brain, snoN transcripts are found predominantly in
the granule neurons of the cerebellum and Purkinje cells in the
cerebellar cortex, in the hippocampus and in the cerebrum
[5,67]. siRNA-based knockdown of SnoN in primary cerebellar
granule and cortical neurons signiﬁcantly reduces axonal growth
[67]. In addition, reducing SnoN in the postnatal rat pups markedly
impairs the morphogenesis of parallel ﬁber axons in the cerebellar
cortex in vivo [48,68]. These results suggest that SnoN may play a
critical role in axon development in the mammalian brain. Mecha-
nistically, SnoN associates with p300/CBP to activate the expres-
sion of the signaling scaffolding protein Ccd1 to promote axon
growth [48]. It can also associate with FOXO1 to repress the
expression of the doublecortin (DCX) gene, and this repression of
DCX expression appears to mediate SnoN regulation of primary
neuron branching and granule neuron migration [69]. SnoN has
also been found to function downstream of the Cdh1–anaphase
promoting complex (Cdh1–APC) and Smad2, and can be degraded
by the Cdh1–APC in neurons [70]. Clearly, more studies are needed
to determine how these events are coordinated to allow SnoN
activity and expression to be controlled in a precise manner to reg-
ulate neuronal speciﬁc functions.
5. SnoN in regulation of aging
SnoN can activate p53 in response to various cellular stress sig-
nals. In primary MEF cells, oxidative stress upregulates SnoN
expression to trigger premature senescence in a p53-dependent
manner [46]. Since activation of p53 is known to accelerate aging
in mice, it is conceivable that SnoNmay also contribute to progeria.
Indeed, the SnoN knockinmice aremore sensitive to environmental
stress and exhibit accelerated aging phenotypes including a short-
ened lifespan, reduced body weight and reproductivity, kyphosis,
osteoporosis, decreased wound-healing ability and a reduced
regenerative capacity [47], similar to that found in mice expressing
an active p53 [71]. Consistent with these aging phenotypes, tissues
from the knockin mice contain an increased number of senescence
and apoptotic cells than those from age-matched WT mice [47].
Thus, in adult cells, SnoN is not just an important negative
regulator of TGF-b signaling, but plays a much broader role in coor-
dinating the cellular stress responses by crosstalk with various
intracellular signaling pathways to regulate cell cycle arrest, senes-
cence and apoptosis. SnoN expression can be induced by a variety of
stress signals and tissue injury. At times of prolonged cellular and
tissue stress and injury, SnoN serves as an important cellular anti-
cancer defense mechanism by integrating various cellular stress
signals to the p53 anti-tumorigenic pathway. These stress re-
sponses protect the organism against cancer development, but at
the price of accelerated aging.6. Conclusion and future directions
Through the analyses of SnoN knockin and knockout mice as
well as examination of primary cells isolated from these mice, a
complex picture of SnoN functions in embryonic and adult tissue
morphogenesis and homeostasis is emerging. An important con-
cept that emerges from these analyses is that SnoN should not be
considered an inhibitor of TGF-b signaling but as an integral and
necessary component of the TGF-b signaling circuit. As a negative
feedback regulator of Smad2/3, it functions to regulate the robust-
ness of signaling. It also coordinates the activities of various signal-
ing pathways of TGF-b signaling branches to ensure that proper
developmental events occur. It is quite likely that our studies thus
far have only uncovered a small fraction of the functions of SnoN innormal tissues. An important goal in the near future is to deter-
mine all the tissue speciﬁc functions of SnoN and to identify their
underlying signaling mechanisms. Understanding these crucial
facts would allow us to apply a systems biology approach to model
the complex signaling network that SnoN regulates.Acknowledgments
Weapologize to theauthorswhoseworkcouldnotbe cited in this
review due to space constraints. Research in the authors’ laboratory
was supported by NIH RO1 CA101891, RO1 DK090347 to K. Luo.References
[1] Li, Y., Turck, C.M., Teumer, J.K. and Stavnezer, E. (1986) Unique sequence, ski,
in Sloan-Kettering avian retroviruses with properties of a new cell-derived
oncogene. J. Virol. 57, 1065–1072.
[2] Nomura, N., Sasamoto, S., Ishii, S., Date, T., Matsui, M. and Ishizaki, R. (1989)
Isolation of human cDNA clones of ski and the ski-related gene, sno. Nucleic
Acids Res. 17, 5489–5500.
[3] Boyer, P.L., Colmenares, C., Stavnezer, E. and Hughes, S.H. (1993) Sequence and
biological activity of chicken snoN cDNA clones. Oncogene 8, 457–466.
[4] Pearson-White, S. (1993) SnoI, a novel alternatively spliced isoform of the ski
protooncogene homolog, sno. Nucleic Acids Res. 21, 4632–4638.
[5] Pelzer, T., Lyons, G.E., Kim, S. and Moreadith, R.W. (1996) Cloning and
characterization of the murine homolog of the sno proto-oncogene reveals a
novel splice variant. Dev. Dyn. 205, 114–125.
[6] Pearson-White, S. and Crittenden, R. (1997) Proto-oncogene Sno expression,
alternative isoforms and immediate early serum response. Nucleic Acids Res.
25, 2930–2937.
[7] Heyman, H.C. and Stavnezer, E. (1994) A carboxyl-terminal region of the ski
oncoprotein mediates homodimerization as well as heterodimerization with
the related protein SnoN. J. Biol. Chem. 269, 26996–27003.
[8] Cohen, S.B., Zheng, G., Heyman, H.C. and Stavnezer, E. (1999) Heterodimers of
the SnoN and Ski oncoproteins form preferentially over homodimers and are
more potent transforming agents. Nucleic Acids Res. 27, 1006–1014.
[9] Luo, K. (2004) Ski and SnoN: negative regulators of TGF-beta signaling. Curr.
Opin. Genet. Dev. 14, 65–70.
[10] Jahchan, N.S. and Luo, K. (2010) SnoN in mammalian development, function
and diseases. Curr. Opin. Pharmacol. 10, 670–675.
[11] Deheuninck, J. and Luo, K. (2009) Ski and SnoN, potent negative regulators of
TGF-beta signaling. Cell Res. 19, 47–57.
[12] Stroschein, S.L., Wang, W., Zhou, S., Zhou, Q. and Luo, K. (1999) Negative
feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science
286, 771–774.
[13] Bonni, S., Wang, H.R., Causing, C.G., Kavsak, P., Stroschein, S.L., Luo, K. and
Wrana, J.L. (2001) TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin
ligase complex that targets SnoN for degradation. Nat. Cell Biol. 3, 587–595.
[14] Stroschein, S.L., Bonni, S., Wrana, J.L. and Luo, K. (2001) Smad3 recruits the
anaphase-promoting complex for ubiquitination and degradation of SnoN.
Genes Dev. 15, 2822–2836.
[15] Wan, Y., Liu, X. and Kirschner, M.W. (2001) The anaphase-promoting complex
mediates TGF-beta signaling by targeting SnoN for destruction. Mol. Cell 8,
1027–1039.
[16] Nagano, Y., Mavrakis, K.J., Lee, K.L., Fujii, T., Koinuma, D., Sase, H., Yuki, K.,
Isogaya, K., Saitoh, M., Imamura, T., Episkopou, V., Miyazono, K. and Miyazawa,
K. (2007) Arkadia induces degradation of SnoN and c-Ski to enhance
transforming growth factor-beta signaling. J. Biol. Chem. 282, 20492–
20501.
[17] Levy, L., Howell, M., Das, D., Harkin, S., Episkopou, V. and Hill, C.S. (2007)
Arkadia activates Smad3/Smad4-dependent transcription by triggering signal-
induced SnoN degradation. Mol. Cell. Biol. 27, 6068–6083.
[18] Le Scolan, E., Zhu, Q., Wang, L., Bandyopadhyay, A., Javelaud, D., Mauviel, A.,
Sun, L. and Luo, K. (2008) Transforming growth factor-beta suppresses the
ability of Ski to inhibit tumor metastasis by inducing its degradation. Cancer
Res. 68, 3277–3285.
[19] Zhu, Q., Pearson-White, S. and Luo, K. (2005) Requirement for the SnoN
oncoprotein in transforming growth factor beta-induced oncogenic
transformation of ﬁbroblast cells. Mol. Cell. Biol. 25, 10731–10744.
[20] Yang, J., Dai, C. and Liu, Y. (2005) A novel mechanism by which hepatocyte
growth factor blocks tubular epithelial to mesenchymal transition. J. Am. Soc.
Nephrol. 16, 68–78.
[21] Tan, R., Zhang, X., Yang, J., Li, Y. and Liu, Y. (2007) Molecular basis for the cell
type speciﬁc induction of SnoN expression by hepatocyte growth factor. J. Am.
Soc. Nephrol. 18, 2340–2349.
[22] Jahchan, N.S., Wang, D., Bissell, M.J. and Luo, K. (2012) SnoN regulates
mammary gland alveologenesis and onset of lactation by promoting prolactin/
STAT5 signaling. Paper submitted.
[23] Macias-Silva, M., Li, W., Leu, J.I., Crissey, M.A. and Taub, R. (2002) Up-regulated
transcriptional repressors SnoN and Ski bind Smad proteins to antagonize
1976 Q. Zhu, K. Luo / FEBS Letters 586 (2012) 1971–1976transforming growth factor-beta signals during liver regeneration. J. Biol.
Chem. 277, 28483–28490.
[24] Mayoral, R., Valverde, A.M., Llorente Izquierdo, C., González-Rodríguez, A.,
Boscá, L. and Martín-Sanz, P. (2010) Impairment of transforming growth factor
beta signaling in caveolin-1-deﬁcient hepatocytes: role in liver regeneration. J.
Biol. Chem. 285, 3633–3642.
[25] Krakowski, A.R., Laboureau, J., Mauviel, A., Bissell, M.J. and Luo, K. (2005)
Cytoplasmic SnoN in normal tissues and nonmalignant cells antagonizes TGF-
beta signaling by sequestration of the Smad proteins. Proc. Natl. Acad. Sci. USA
102, 12437–12442.
[26] Jahchan, N.S., You, Y.H., Muller, W.J. and Luo, K. (2010) Transforming growth
factor-beta regulator SnoN modulates mammary gland branching
morphogenesis, postlactational involution, and mammary tumorigenesis.
Cancer Res. 70, 4204–4213.
[27] Shi, Y. and Massague, J. (2003) Mechanisms of TGF-beta signaling from cell
membrane to the nucleus. Cell 113, 685–700.
[28] Massagué, J. (2008) TGFbeta in cancer. Cell 134, 215–230.
[29] Mummery, C.L. (2001) Transforming growth factor beta and mouse
development. Microsc. Res. Tech. 52, 374–386.
[30] Derynck, R., Miyazono, K. (2008) TGF-b and the TGF-b family in: The TGF-b
Family (Derynck, R., Miyazono, K., Eds.), pp. 29–44. Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, NY.
[31] Wu, M.Y. and Hill, C.S. (2009) TGF-beta superfamily signaling in embryonic
development and homeostasis. Dev. Cell 16, 329–343.
[32] Guo, X. andWang, X.F. (2009) Signaling cross-talk between TGF-beta/BMP and
other pathways. Cell Res. 19, 71–88.
[33] Brennan, J., Lu, C.C., Norris, D.P., Rodriguez, T.A., Beddington, R.S. and
Robertson, E.J. (2001) Nodal signalling in the epiblast patterns the early
mouse embryo. Nature 411, 965–969.
[34] ten Dijke, P. and Arthur, H.M. (2007) Extracellular control of TGFbeta signalling
in vascular development and disease. Nat. Rev. Mol. Cell Biol. 8, 857–869.
[35] Massagué, J., Seoane, J. and Wotton, D. (2005) Smad transcription factors.
Genes Dev. 19, 2783–2810.
[36] Feng, X.H. and Derynck, R. (2005) Speciﬁcity and versatility in TGF-signaling
through Smads. Annu. Rev. Cell Dev. Biol. 21, 659–693.
[37] Moustakas, A. and Heldin, C.H. (2009) The regulation of TGFbeta signal
transduction. Development 136, 3699–3714.
[38] Attisano, L. and Wrana, J.L. (2002) Signal transduction by the TGF-beta
superfamily. Science 296, 1646–1647.
[39] Akiyoshi, S., Inoue, H., Hanai, J., Kusanagi, K., Nemoto, N., Miyazono, K. and
Kawabata, M. (1999) C-Ski acts as a transcriptional co-repressor in
transforming growth factor-beta signaling through interaction with smads. J.
Biol. Chem. 274, 35269–35277.
[40] Wu, J.W., Krawitz, A.R., Chai, J., Li, W., Zhang, F., Luo, K. and Shi, Y. (2002)
Structural mechanism of Smad4 recognition by the nuclear oncoprotein Ski:
insights on Ski-mediated repression of TGF-beta signaling. Cell 111, 357–
367.
[41] He, J., Tegen, S.B., Krawitz, A.R., Martin, G.S. and Luo, K. (2003) The
transforming activity of Ski and SnoN is dependent on their ability to
repress the activity of Smad proteins. J. Biol. Chem. 278, 30540–30547.
[42] Sun, Y., Liu, X., Ng-Eaton, E., Lodish, H.F. and Weinberg, R.A. (1999) SnoN and
Ski protooncoproteins are rapidly degraded in response to transforming
growth factor beta signaling. Proc. Natl. Acad. Sci. USA 96, 12442–12447.
[43] Zhu, Q., Krakowski, A.R., Dunham, E.E., Wang, L., Bandyopadhyay, A., Berdeaux,
R., Martin, G.S., Sun, L. and Luo, K. (2007) Dual role of SnoN in mammalian
tumorigenesis. Mol. Cell. Biol. 27, 324–339.
[44] Sarker, K.P., Wilson, S.M. and Bonni, S. (2005) SnoN is a cell type-speciﬁc
mediator of transforming growth factor-beta responses. J. Biol. Chem. 280,
13037–13046.
[45] Sarker, K.P., Kataoka, H., Chan, A., Netherton, S.J., Pot, I., Huynh, M.A., Feng, X.,
Bonni, A., Riabowol, K. and Bonni, S. (2008) ING2 as a novel mediator of
transforming growth factor-beta-dependent responses in epithelial cells. J.
Biol. Chem. 283, 13269–13279.
[46] Pan, D., Zhu, Q. and Luo, K. (2009) SnoN functions as a tumour suppressor by
inducing premature senescence. EMBO J. 28, 3500–3513.
[47] Pan, D., Zhu, Q., Conboy, M.J., Conboy I.M. and Luo, K. (2012) SnoN directly
activates p53 to regulate aging and tumorigenesis. Paper submitted.
[48] Ikeuchi, Y., Stegmüller, J., Netherton, S., Huynh, M.A., Masu, M., Frank, D.,
Bonni, S. and Bonni, A. (2009) A SnoN-Ccd1 pathway promotes axonal
morphogenesis in the mammalian brain. J. Neurosci. 29, 12–21.[49] Shinagawa, T., Dong, H.-D., Xu, M., Maekawa, T. and Ishii, S. (2000) The sno
gene, which encodes a component of the histone deacetylation complex, acts
as a tumor suppressor in mice. EMBO J. 19, 2280–2291.
[50] Pearson-White, S. and McDufﬁe, M. (2003) Defective T-cell activation is
associated with augmented transforming growth factor Beta sensitivity in
mice with mutations in the Sno gene. Mol. Cell. Biol. 23, 5446–5459.
[51] Pardali, E., Goumans, M.J. and ten Dijke, P. (2010) Signaling by members of the
TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol. 20,
556–567.
[52] Seki, T., Hong, K.H. and Oh, S.P. (2006) Nonoverlapping expression patterns of
ALK1 and ALK5 reveal distinct roles of each receptor in vascular development.
Lab. Invest. 86, 116–129.
[53] Urness, L.D., Sorensen, L.K. and Li, D.Y. (2000) Arteriovenous malformations in
mice lacking activin receptor-like kinase-1. Nat. Genet. 26, 328–331.
[54] Seki, T., Yun, J. and Oh, S.P. (2003) Arterial endothelium-speciﬁc activin
receptor-like kinase 1 expression suggests its role in arterialization and
vascular remodeling. Circ. Res. 93, 682–689.
[55] Yang, X., Castilla, L.H., Xu, X., Li, C., Gotay, J., Weinstein, M., Liu, P.P. and Deng,
C.X. (1999) Angiogenesis defects and mesenchymal apoptosis in mice lacking
SMAD5. Development 126, 1571–1580.
[56] Goumans, M.J., Valdimarsdottir, G., Itoh, S., Rosendahl, A., Sideras, P. and ten
Dijke, P. (2002) Balancing the activation state of the endothelium via two
distinct TGF-beta type I receptors. EMBO J. 21, 1743–1753.
[57] Arnold, S.J. and Robertson, E.J. (2009) Making a commitment: cell lineage
allocation and axis patterning in the early mouse embryo. Nat. Rev. Mol. Cell
Biol. 10, 91–103.
[58] Levine, A.J. and Brivanlou, A.H. (2007) Proposal of a model of mammalian
neural induction. Dev. Biol. 308, 241–256.
[59] Zhang, F., Lundin, M., Ristimaki, A., Heikkila, P., Lundin, J., Isola, J., Joensuu, H.
and Laiho, M. (2003) Ski-related novel protein N (SnoN), a negative controller
of transforming growth factor-beta signaling, is a prognostic marker in
estrogen receptor-positive breast carcinomas. Cancer Res. 63, 5005–5010.
[60] Zhang, X., Egawa, K., Xie, Y. and Ihn, H. (2009) The expression of SnoN in
normal human skin and cutaneous keratinous neoplasms. Int. J. Dermatol. 48,
579–583.
[61] Neville, M.C., McFadden, T.B. and Forsyth, I. (2002) Hormonal regulation of
mammary differentiation and milk secretion. J. Mammary Gland Biol.
Neoplasia 7, 49–66.
[62] Oakes, S.R., Hilton, H.N. and Ormandy, C.J. (2006) The alveolar switch:
coordinating the proliferative cues and cell fate decisions that drive the
formation of lobuloalveoli from ductal epithelium. Breast Cancer Res. 8, 207.
[63] Richert, M.M., Schwertfeger, K.L., Ryder, J.W. and Anderson, S.M. (2000) An
atlas of mouse mammary gland development. J. Mammary Gland Biol.
Neoplasia 5, 227–241.
[64] Anderson, S.M., Rudolph, M.C., McManaman, J.L. and Neville, M.C. (2007) Key
stages in mammary gland development. Secretory activation in the mammary
gland: it’s not just about milk protein synthesis! Breast Cancer Res. 9, 204.
[65] Bierie, B. and Moses, H.L. (2006) Tumour microenvironment: TGFbeta: the
molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6, 506–520.
[66] Muraoka-Cook, R.S., Shin, I., Yi, J.Y., Easterly, E., Barcellos-Hoff, M.H., Yingling,
J.M., Zent, R. and Arteaga, C.L. (2006) Activated type I TGFbeta receptor kinase
enhances the survival of mammary epithelial cells and accelerates tumor
progression. Oncogene 25, 3408–3423.
[67] Stegmüller, J., Konishi, Y., Huynh, M.A., Yuan, Z., Dibacco, S. and Bonni, A.
(2006) Cell-intrinsic regulation of axonal morphogenesis by the Cdh1–APC
target SnoN. Neuron 50, 389–400.
[68] Pot, I., Ikeuchi, Y., Bonni, A. and Bonni, S. (2010) SnoN: bridging neurobiology
and cancer biology. Curr. Mol. Med. 10, 667–673.
[69] Huynh, M.A., Ikeuchi, Y., Netherton, S., de la Torre-Ubieta, L., Kanadia, R.,
Stegmüller, J., Cepko, C., Bonni, S. and Bonni, A. (2011) An isoform-speciﬁc
SnoN1-FOXO1 repressor complex controls neuronal morphogenesis and
positioning in the mammalian brain. Neuron 69, 930–944.
[70] Stegmüller, J., Huynh, M.A., Yuan, Z., Konishi, Y. and Bonni, A. (2008) TGFbeta-
Smad2 signaling regulates the Cdh1–APC/SnoN pathway of axonal
morphogenesis. J. Neurosci. 28, 1961–1969.
[71] Tyner, S.D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H.,
Lu, X., Soron, G., Cooper, B., Brayton, C., Hee Park, S., Thompson, T., Karsenty, G.,
Bradley, A. and Donehower, L.A. (2002) P53 mutant mice that display early
ageing-associated phenotypes. Nature 415, 45–53.
